Literature DB >> 1267442

Synergy of mecillinam (FL1060) with penicillins and cephalosporins against Proteus and Klebsiella, with observations on combinations with other antibiotics and against other bacterial species.

R S Baltimore, J O Klein, C Wilcox, M Finland.   

Abstract

Thirty-five strains each of Klebsiella and Proteus were tested for susceptibility to mecillinam alone and in combination with ampicillin, carbenicillin, cephalothin, and cefazolin. Antibiotics were considered to be synergistic when there was a >/=fourfold reduction in minimum inhibiting concentration of both antibiotics in the combination as compared with that of each antibiotic alone. Synergy of mecillinam with ampicillin, carbenicillin, cephalothin, and cefazolin was demonstrated against 2, 3, 7, and 8 of the 35 strains of Klebsiella and against 14, 14, 19, and 24 of the 35 strains of Proteus, respectively. Synergy against the isolates of Proteus was related to species, whereas against Klebsiella it was related to susceptibility of the isolates to mecillinam. Tests of combinations of mecillinam with other antibiotics on the same and different species indicated that synergy was related to the antibiotic, the species, and the strains of organisms tested.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1267442      PMCID: PMC429601          DOI: 10.1128/AAC.9.4.701

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Mecillinam (FL 1060), a 6beta-amidinopenicillanic acid derivative: in vitro evaluation.

Authors:  L Tybring
Journal:  Antimicrob Agents Chemother       Date:  1975-09       Impact factor: 5.191

2.  FL-1060: a new penicillin with a unique mode of action.

Authors:  J T Park; L Burman
Journal:  Biochem Biophys Res Commun       Date:  1973-04-16       Impact factor: 3.575

3.  Light and electron microscopy of the early response of Escherichia coli to a 6beta-amidinopenicillanic acid (FL 1060).

Authors:  N H Melchior; J Blom; L Tybring; A Birch-Andersen
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1973-08

4.  6 -amidinopenicillanic acids--a new group of antibiotics.

Authors:  F Lund; L Tybring
Journal:  Nat New Biol       Date:  1972-04-05

5.  Use of gentamicin in combinations with other antibiotics.

Authors:  C B Smith; P E Dans; J N Wilfert; M Finland
Journal:  J Infect Dis       Date:  1969 Apr-May       Impact factor: 5.226

6.  Antibiotic susceptibility of gram-negative bacilli isolated from blood cultures. Results of tests with 35 agents and strains from 169 patients at Boston City Hospital during 1972.

Authors:  J E McGowan; C Garner; C Wilcox; M Finland
Journal:  Am J Med       Date:  1974-08       Impact factor: 4.965

7.  In vivo synergy between 6 beta-amidinopenicillanic acid derivatives and other antibiotics.

Authors:  E Grunberg; R Cleeland; G Beskid; W F DeLorenzo
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

8.  Mecillinam (FL 1060), a 6beta-amidinopenicillanic acid derivative: bactericidal action and synergy in vitro.

Authors:  L Tybring; N H Melchior
Journal:  Antimicrob Agents Chemother       Date:  1975-09       Impact factor: 5.191

9.  FL 1060: a new beta-lactam antibiotic with novel properties.

Authors:  D Greenwood; F O'Grady
Journal:  J Clin Pathol       Date:  1973-01       Impact factor: 3.411

10.  Synergistic action of ampicillin and erythromycin against Nocardia asteroides: effect of time of incubation.

Authors:  M Finland; M C Bach; C Garner; O Gold
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191

  10 in total
  11 in total

1.  Combinations of beta lactam antibiotics.

Authors:  S J Pedler; A J Bint
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-07

2.  Pharmacokinetics of intravenous amdinocillin in healthy subjects and patients with renal insufficiency.

Authors:  I H Patel; L D Bornemann; V M Brocks; L S Fang; N E Tolkoff-Rubin; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

3.  Activity of semisynthetic penicillins and synergism with mecillinam against Bacteroides species.

Authors:  I Trestman; D Kaye; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

4.  Comparison of the effects of mecillinam and 6-aminopenicillanic acid on Proteus mirabilis, Escherichia coli, and Staphylococcus aureus.

Authors:  V Lorian; B Atkinson
Journal:  Antimicrob Agents Chemother       Date:  1977-03       Impact factor: 5.191

5.  Mecillinam alone and in combination with ampicillin or moxalactam in experimental Escherichia coli meningitis.

Authors:  U B Schaad; L M Grimm; G Beskid; R Cleeland; J D Nelson; G H McCracken
Journal:  Infection       Date:  1982       Impact factor: 3.553

6.  Synergy of mecillinam, a beta-amidinopenicillanic acid derivative, combined with beta-lactam antibiotics.

Authors:  J C Neu
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

7.  New cephamycin antibiotic, CS-1170: binding affinity to penicillin-binding proteins and inhibition of peptidoglycan cross-linking reactions in Escherichia coli.

Authors:  S Ohya; M Yamazaki; S Sugawara; S Tamaki; M Matsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

8.  Comparison of the binding properties of two 6 beta-amidinopenicillanic acid derivatives that differ in their physiological effects on Escherichia coli.

Authors:  B G Spratt
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

9.  Inhibitory activity and bactericidal kinetics of mecillinam/ampicillin combinations against Enterobacteriaceae, Pseudomonas and Acinetobacter.

Authors:  J E Fuglesang; T Bergan; T Bielecki; A Naterstad; E Namork
Journal:  Infection       Date:  1981       Impact factor: 3.553

10.  Pharmacokinetics of mecillinam in health subjects.

Authors:  J G Gambertoglio; S L Barriere; E T Lin; J E Conte
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.